• Alexandre Cesar Vieira de Sales, Isaura Isabelle Fonseca Gomes da Silva, Matheus Carvalho Brito Leite, Leandro de Lima Coutinho, Renata Bezerra de Albuquerque Cavalcante Reis, Danyelly Bruneska Gondin Martins, José Luiz de Lima Filho, and Oliveira SoutoFabrícioF0000-0002-2392-8499Laboratorio de Imunopatologia Keizo Asami (LIKA), Universidade Federal de Pernambuco (UFPE), Recife, PE, BR.Nucleo de Ciencias da Vida (NCV), Centro Academico do Agreste (CAA), Universidade Federal de Pernambuco (.
• Laboratorio de Imunopatologia Keizo Asami (LIKA), Universidade Federal de Pernambuco (UFPE), Recife, PE, BR.
• Clinics (Sao Paulo). 2021 Jan 1; 76: e2142.

ObjectiveThis study aimed to assess miRNA-195 expression in the tumor tissues from a cohort of Brazilian female breast cancer patients undergoing neoadjuvant chemotherapy (NAC) and evaluate its correlation with various clinicopathological markers.MethodsQuantitative reverse transcription polymerase chain reaction (qRT-PCR) was used to evaluate the miRNA-195 expression in tumor tissues from a cohort of female breast cancer patients undergoing NAC. This expression was then correlated with the occurrence of several distinct breast cancer molecular subtypes and other clinicopathological variables.ResultsA total of 55 patients were included in this study, 28 (50.9%) of whom were treated using NAC. Tumor miRNA-195 expression was suppressed in breast cancer patients, regardless of their exposure to systemic treatments, histological grade, size, nodal status, and tumor-node-metastasis (TNM) staging. This was more pronounced in luminal and triple-negative patients, and patient's response to NAC was correlated with an increase in miRNA-195 expression.ConclusionmiRNA-195 is downregulated in the tumor tissues of Brazilian breast cancer patients regardless of NAC exposure; this reinforces its role as a tumor suppressor and a potential biomarker for chemotherapy response.

16 keywords...

hide…